Uroplakin III (AU-1) Mouse Monoclonal Antibody
SIGMA/345M-1
Product Type: Chemical
Immunohistochemistry Uroplakin III (AU-1) on transitional cell carcinoma
| antibody form | culture supernatant |
| antibody product type | primary antibodies |
| biological source | mouse |
| clone | AU-1, monoclonal |
| conjugate | unconjugated |
| control | bladder |
| description | For In Vitro Diagnostic Use in Select Regions (See Chart) |
| form | buffered aqueous solution |
| isotype | IgG1 |
| manufacturer/tradename | Cell Marque™ |
| packaging | bottle of 1.0 mL predilute (345M-17) |
| bottle of 7.0 mL predilute (345M-18) | |
| vial of 0.1 mL concentrate (345M-14) | |
| vial of 0.5 mL concentrate (345M-15) | |
| vial of 1.0 mL concentrate (345M-16) | |
| Quality Level | 100  |
| 500 |
|
| shipped in | wet ice |
| species reactivity | human |
| storage temp. | 2-8°C |
| technique(s) | immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100 |
| visualization | membranous |
| General description: | Uroplakins (UPs) are a family of transmembrane proteins (UPs Ia, Ib, II and III) that are specific differentiation products of urothelial cells. In non-neoplastic mammalian urothelium, UPs are expressed in the luminal surface plasmalemma of superficial (umbrella) cells, forming complexes of 16-nm crystalline particles. Moll et al. reported that UPIII was detectable immunohistochemically in 29 of 55 primary (53%) and 23 of 35 metastatic (66%) urothelial carcinomas, whereas many non-urothelial carcinomas were UPIII-negative. The authors concluded that UPIII should be a valuable marker, especially for the specific identification of urothelial carcinomas in patients with metastases of unknown primary site. Recently, Olsburgh et al. studied UP gene expression in normal urothelium and bladder cancer specimens, and found that expression was absent after malignant transformation. Thus, UP expression might reflect the malignant potential of urothelial cancer cells as well as being cytodifferential markers of urothelial cells. Ohtsuka et al. concluded in their studies that UPIII expression was strongly associated with lower tumor grades, that lack of UPIII expression in urothelial tumors of the upper urinary tract was associated with much higher rates of metastases, and that 5-year specific survival was much worse for UPIII negative tumors (54%) than for UPIII positive tumors (100%). Apparently UPIII expression is a better indicator of the malignant potential of the tumour than the grade of the tumour. Associated products: Thrombomodulin, CK7, CK20 |
||||
| Legal Information: | Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany | ||||
| Linkage: | Uroplakin III Positive Control Slides, Product No. 345S , are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections). |
||||
| Other Notes: | For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com | ||||
| Physical form: | Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide | ||||
| Preparation Note: | Download the IFU specific to your product lot and format  Note: This requires a keycode which can be found on your packaging or product label. |
||||
| Quality: |
|
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |